Government projects
Fundamental grant (2017-2020):
ССВ-Ф-002“Study of the pathogenetic role of micro RNA in the development of fibrosis and primary liver cancer in chronic HBV, HCV and HDV- infections".
Applied grants for young scientists (2018-2019):
MU-PZ-20171023175 "Development of diagnostics HCC by PIVKA II method in chronic viral hepatitis in Uzbekistan".
MU-PZ-20171023165 “Clinical and laboratory features of the course of insulin resistance, metabolic syndrome against the background of chronic viral hepatitis “C” and the economic burden of late detection of this comorbid condition".
MU-PZ-20171025453 "Study of the effect of synanthropic ectoparasitic ticks on the viral load of salivary glands, as well as the development of new tools and methods for regulating tick numbers".
MU-PZ-20171025174 "Development of a diagnostic algorithm for hantavirus infection".
Applied grants (2018-2020):
PZ-2017090726 "Development of methods for assessing the risk of developing liver cirrhosis and hepatocellular carcinoma as a result of various types of chronic hepatitis B and D, and a differentiated approach to their prognosis, prevention and treatment".
PZ-2017090828 "Development of clinical, epidemiological and laboratory criteria for parvovirus infection in Uzbekistan".
Applied grants (2020-2021):
FZ-202004065 “Creation of technology for the fight against and treatment of coronavirus infections based on an in-depth analysis of pathogenesis (2020-2021)”.
Innovation grant (2020-2021)
S-I-45 Conducting clinical trials of the drug "Rutan tablets 0.1g" No. 10 in the complex therapy of the viral disease COVID-19
Applied Research Project (2020–2022):
FZ-202004065 “Development of a technology to combat and treat Coronavirus infection based on an in-depth analysis of its pathogenesis”.
Innovation grant (2021-2022)
Study of the effectiveness of the domestic drug Rutan in children in the treatment of COVID-19, ARVI and the development of treatment protocols.
Applied Research Project (2023–2026):
“Identification of Host factors and biomarkers involved in the development of hepatocellular carcinoma associated with HBV, HDV and HCV infections, and cervical cancer”.
Applied grants (2024-2025):
AL-742210838 “Development of personalized diagnostic and treatment technologies in the context of counteracting the spread of certain current viral and other infections (long covid, tuberculosis, chronic viral hepatitis C) in patients with HIV (human immunodeficiency virus) infection”.
AL-742210838 Optimization of early diagnosis of liver fibrosis and hepatocellular carcinoma due to viral hepatitis among the population of the republic
AL-18-722212905 “Optimization of early diagnosis of liver fibrosis and hepatocellular carcinoma due to viral hepatitis among the population republics".
FL-9524115067 Molecular genetic mechanisms that determine the risk of infection, severity and prognosis of HDV infection
Applied Research Project (2024–2025):
AL-742210838 “Optimization of early diagnosis of liver fibrosis and hepatocellular carcinoma associated with viral hepatitis among the population of the Republic”.
AL-18-722212905 “Development of personalized diagnostic and treatment technologies to counteract the spread of certain emerging viral and other infections (Long-COVID-19, tuberculosis, and chronic hepatitis C) in patients with HIV (Human immunodeficiency virus) infection”.
Fundamental Research Project (April 2025 – April 2028):
FL-9524115067 “Molecular genetic mechanisms determining the risk of infection, disease severity, and prognosis of HDV infection”.
Applied Research Project (February 2026 – January 31, 2028):
AL-9925025511 “Clinical and epidemiological significance of Torque teno virus in the development and course of human infectious diseases”.
AL-9925025516 “Frequency and characteristics of viral liver damage in children receiving chemotherapy for hematologic malignancies”.